Introducing The Next Generation ofContinuous Glucose Monitoring
The GlySens Eclipse 3
nothing attached to the body - lasts for years
Developed over many years, the Eclipse 3 sensor employs a number of unique and groundbreaking technologies to ensure a long lasting and accurate device
Granted and Pending Patents
Human Clinical Trials Completed
The chief leaders at GlySens are renowned professionals with deep experience in the medical device field. They lead an accomplished and dedicated team of R&D, operational, quality, marketing and regulatory professionals. Our medical and business advisory group is comprised of highly experienced clinicians, corporate, financial, legal and IP resource experts.
William H. Markle
President & CEO
William (Bill) Markle is President and CEO of GlySens. Mr. Markle has a 30-year track record of successful product and global market development, clinical evaluation, and visionary leadership in the medical device field. He was formerly founder, President, and CEO of GluMetrics, Inc. At GluMetrics, he directed the successful development of continuous real-time sensing technology for intravascular glucose monitoring in the intensive care and operating room environment. Previously, he held senior executive positions in marketing and business development at Tensys Medical and Masimo Corporation, and related positions at Baxter Edwards Critical Care and American Hospital Supply. Mr. Markle is an MBA graduate of Pepperdine University and an engineering graduate of Duke University. He is a named inventor on numerous issued U.S. patents and published applications.
Tim L. Routh
Regulatory Affairs & Quality Assurance
Product Strategy and Software
Bruce Buckingham, MD
Dr. Bruce Buckingham received his medical degree from University of California at San Diego. He completed his internship, residency, and fellowship at Children’s Hospital of Los Angeles. He is currently a Professor in the Department of Pediatric Endocrinology at Stanford Medical Center and the Stanford Children’s Hospital. His research focuses on continuous glucose monitoring in children and closed-loop (artificial pancreas) systems. He has collaborated on various overnight and 24-hour closed-loop platforms in development and has helped to develop algorithms for detecting infusion set and sensor failures and to improve infusion set wear duration.
Dr. Buckingham is well recognized as a leading expert in the real-world application and clinical use of continuous glucose monitoring systems.
Daniel Einhorn, MD
Dr. Daniel Einhorn is medical director of the Scripps Whittier Diabetes Institute, clinical professor of medicine (voluntary) at UC San Diego, president of Diabetes and Endocrine Associates, and associate editor of the Journal of Diabetes. He is a trustee and past-president of the American College of Endocrinology (ACE), a founding member and regent of the ACE Foundation, and past-president of the American Association of Clinical Endocrinologists (AACE). He received his BA at Yale (Summa cum Laude), his MD at Tufts (AOA) and his post-graduate training at Harvard. He has been in a leadership position in endocrinology for over 20 years during which time he has had the privilege of co-writing many national guidelines, including those for diabetes, pre-diabetes, inpatient diabetes management, and obesity, as well as leading consensus conferences on insulin resistance, pre-diabetes, obesity, and glucose monitoring. He has won the highest awards from AACE, ACE, and the Endocrine Society as well as numerous other honors. He has been on hundreds of teaching programs, written dozens of papers and chapters on diabetes, served on many dozens of scientific advisory committees, and has participated in clinical research on virtually all classes of diabetes therapies and diagnostics. He continues to be a practicing physician who loves seeing patients and their families and who appreciates the real world education he gets from them every day.
Daniel P. Connally, CFA, Principal, Fayez Sarofim & Co.
Robert L. Engler, MD, Professor of Medicine, Emeritus, University of California, San Diego
Adam E. Fine, MBA, Founder and Managing Partner, Windham Venture Partners
Orville G. Kolterman, MD, Clinical & Regulatory Expert, former CMO, Amylin Pharmaceuticals, Inc.
William H. Markle, President and CEO, GlySens Incorporated
R. Cary McNair, Chairman and CEO, McNair Interests
Richard P. Thompson, Diabetes Entrepreneur and past President and CEO of ReShape Medical, Inc.
3931 Sorrento Valley Blvd.
San Diego, California 92121
+1 (858) 638-7708
Want to learn more? Please send us an email or call our office, we would love to hear from you.Email Us
CAUTION - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.
Sign up to stay informed on the latest from GlySens
CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use.
Illustrations are for demonstration purposes only
GlySens® and Eclipse® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.